Kyverna Therapeutics (KYTX) Operating Income (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Operating Income of -$41.4 million for Q1 2026, down 5.31% on a QoQ basis from -$39.3 million in Q4 2025, and up 12.74% year-over-year from -$36.7 million in Q1 2025.
Kyverna Therapeutics (KYTX) Operating Income (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Operating Income history runs 4 years deep, the most recent figure standing at -$41.4 million for Q1 2026.
- Quarterly Operating Income rose 12.74% year-over-year to -$41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$163.8 million (down 1.95% YoY) and the FY2025 annual result came in at -$169.8 million, down 19.09% from the prior year.
- Operating Income was -$41.4 million for Q1 2026 at Kyverna Therapeutics, down from -$39.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$11.4 million in Q1 2023 and bottomed at -$47.4 million in Q1 2025.
- A 4-year average of -$32.0 million and a median of -$38.7 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income sank 156.51% — and 2026, when it gained 12.74%.
- Kyverna Therapeutics' Operating Income stood at -$21.4 million in 2023, then sank by 91.99% to -$41.0 million in 2024, then increased by 4.29% to -$39.3 million in 2025, then fell by 5.31% to -$41.4 million in 2026.
- Business Quant data shows KYTX's Operating Income at -$41.4 million in Q1 2026, -$39.3 million in Q4 2025, and -$38.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Kyverna Therapeutics | 447.52 Mn | 447.52 Mn | - | -41.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.37 Mn |
| Dec 31, 2025 | -39.28 Mn |
| Sep 30, 2025 | -38.73 Mn |
| Jun 30, 2025 | -44.41 Mn |
| Mar 31, 2025 | -47.41 Mn |
| Dec 31, 2024 | -41.04 Mn |
| Sep 30, 2024 | -38.77 Mn |
| Jun 30, 2024 | -33.44 Mn |
| Mar 31, 2024 | -29.36 Mn |
| Dec 31, 2023 | -21.38 Mn |
| Sep 30, 2023 | -16.28 Mn |
| Jun 30, 2023 | -13.30 Mn |
| Mar 31, 2023 | -11.45 Mn |